| D(HBsAg+)/R(HBsAg-) group (n = 83) | D(HBcAb+)/R(HBcAb-) group (n = 83) | P value |
---|---|---|---|
Donors’ pre-transplant HBV serology | |||
 HBsAg+ | 83 (100%) | 0 | < 0.001 |
 HBsAb+ | 3 (3.6%) | 58 (69.9%) | < 0.001 |
 HBeAg+ | 0 | 0 | / |
 HBeAb+ | 78 (94.0%) | 35 (42.2%) | < 0.001 |
 HBcAb+ | 82 (98.8%) | 83 (100%) | 1.000 |
 HBV DNA+ | 24 (28.9%) | Unknowna | / |
Recipients’ pre-transplant HBV serology | |||
 HBsAg+ | 0 | 0 | / |
 HBsAb+ | 63 (75.9%) | 63 (75.9%) | 1.000 |
  HBsAb titer > 100 | 32 (38.6%) | 32 (38.6%) | 1.000 |
 HBeAg+ | 0 | 0 | / |
 HBeAb+ | 34 (41.0%) | 0 | < 0.001 |
 HBcAb+ | 58 (69.9%) | 0 | < 0.001 |
 HBV DNA+ | 0 | Unknowna | / |
Recipients’ most recent HBV serology | |||
 HBV DNA - → + | 2b (2.4%) | 0 | 0.477 |
 HBsAg - → + | 2b (2.4%) | 0 | 0.477 |
 HBeAg - → + | 1 (1.2%) | 0 | 1.000 |
 HBeAb - → + | 4 (4.8%) | 0 | 0.129 |
 HBeAb + → - | 4 (4.8%) | 0 | 0.129 |
 HBcAb - → + | 7 (8.4%) | 2 (2.4%) | 0.170 |
 HBsAb titer downgrade | 1 (1.2%) | 11 (13.3%) | 0.012 |
 HBsAb titer upgrade | 13 (15.7%) | 2 (2.4%) | 0.013 |
Recipients’ post-transplant complications | |||
 Treatment failure | 18 (21.7%) | 9 (10.8%) | < 0.001 |
 Delayed graft function | 2 (2.4%) | 0 | 0.477 |
 Rejection | 12 (14.5%) | 12 (14.5%) | 1.000 |
 Infection | 34 (41.0%) | 22 (26.5%) | 0.071 |
 Graft loss | 4 (4.8%) | 4 (4.8%) | 1.000 |
 Recipient death | 5 (6.0%) | 1 (1.2%) | 0.216 |
 Abnormal liver function | 29 (34.9%) | 32 (38.6%) | 0.650 |
  Active liver injury | 8 (9.6%) | 2 (2.4%) | 0.048 |
 Malignancy | 0 | 0 | / |